08:00 Tue 24 Apr 2018
Sareum Holdings PLC - Sareum to Present at BioTrinity 2018 in London
(AIM: SAR)
("Sareum" or the "Company")
Sareum to Present at BioTrinity 2018 in London
Presentation details are as follows:
Date: Tuesday
Time: 12.20
Location: Plenary Hall Two, Novotel London West
BioTrinity is one of Europe's leading biopartnering and investment conferences, and the largest of its type in the UK. The event is attended by global life sciences investors, big pharma executives and emerging R&D companies.
For further information, please contact:
|
|
Tim Mitchell |
01223 497 700 |
|
|
Chris Fielding / James Sinclair-Ford |
020 7220 1666 |
|
|
Claire Noyce |
020 3764 2341 |
Citigate Dewe Rogerson (Media enquiries) |
|
Shabnam Bashir/ Mark Swallow/ David Dible |
020 7282 9571 |
Notes for editors:
Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.
Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.
The Company's drug discovery technology platform (SKIL® -
- Ends -
This information is provided by RNS
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE